RT Journal Article
SR Electronic
T1 Monitoring the rise of the SARS-CoV-2 lineage B.1.1.7 in Tenerife (Spain) since mid-December 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.14.21253535
DO 10.1101/2021.03.14.21253535
A1 Alcoba-Florez, Julia
A1 Lorenzo-Salazar, Jose M.
A1 Gil-Campesino, Helena
A1 Íñigo-Campos, Antonio
A1 de Artola, Diego García-Martínez
A1 García-Olivares, Victor
A1 Díez-Gil, Oscar
A1 Valenzuela-Fernández, Agustín
A1 Ciuffeda, Laura
A1 González-Montelongo, Rafaela
A1 Flores, Carlos
YR 2021
UL http://medrxiv.org/content/early/2021/03/15/2021.03.14.21253535.abstract
AB Starting in December 2020, a sharp increase of COVID-19 cases occurred in Tenerife compared to the rest of the Canary Islands (Spain). Because of the direct touristic connections between Tenerife and the UK, and the rapid transmission and dominance of the SARS-CoV-2 B.1.1.7 variant of concern (VOC-202012/01) by the end of November 2020 in South England, here we measured the proportion of B.1.1.7 cases occurring between the 18th of December 2020 and the 25th of February 2021. Out of the 2,091 COVID-19 positive nasopharyngeal swab samples assessed, 226 showed a spike gene target failure (SGTF). Subsequent viral genome sequencing further confirmed that 93.2% of them corresponded to the B.1.1.7 lineage. Furthermore, a rapid increase in the proportion of SGTF variants was detected in up to 10.7% of positive cases during the Christmas season despite stricter measures for containing the transmission were imposed in Tenerife in the period. These results support the local transmission of SARS-CoV-2 B.1.1.7 lineage in Tenerife since late December 2020 although it is not yet dominant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by Cabildo Insular de Tenerife [grants CGIEU0000219140 and Apuestas cientificas del ITER para colaborar en la lucha contra la COVID-19]; the agreement with Instituto Tecnologico y de Energias Renovables (ITER) to strengthen scientific and technological education, training research, development and innovation in Genomics, Personalized Medicine and Biotechnology [grant number OA17/008]; Ministerio de Ciencia e Innovacion [grant numbers RTI2018-093747-B-100 and RTC-2017-6471-1], co-funded by the European Regional Development Fund (ERDF); Lab P2+ facility [grant number UNLL10-3E-783], co-funded by the ERDF and Fundacion CajaCanarias; and the Spanish HIV/AIDS Research Network [grant number RIS-RETIC, RD16/0025/0011], co-funded by Instituto de Salud Carlos III and by the ERDF; and ProID2020010093 (RIS-3 Canarias Strategy - Maria del Carmen Betancourt y Molina Program, Consejeria de Economia, Conocimiento y Empleo, Gobierno de Canarias). The funders had no role in the study design, collection, analysis and interpretation of data, in the writing of the manuscript or in the decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University Hospital Nuestra Señora de Candelaria (Santa Cruz de Tenerife, Spain) review board approved the study (ethics approval number: CHUNSC_2020_24).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be publicly available through GISAID.